QCZ484

DRUG4 trials

Sponsors

Novartis Pharmaceuticals

Conditions

HypercholesterolaemiaHypertensionHypertension (HTN)Mild Hypertension

Phase 1

A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects

CompletedNCT06905327

Novartis PharmaceuticalsMild Hypertension

Start: 2023-03-08End: 2025-07-01Updated: 2026-07-09

Phase 2

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

Active, not recruitingNCT06857955

Novartis PharmaceuticalsHypertension

Start: 2025-03-26End: 2028-04-05Updated: 2026-09-04

An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

RecruitingNCT07543120

Novartis PharmaceuticalsHypertension (HTN)

Start: 2026-05-07End: 2031-11-30Target: 323Updated: 2026-07-30

A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia

RecruitingNCT07610278

Novartis PharmaceuticalsHypercholesterolaemia

Start: 2026-05-29End: 2028-02-03Target: 120Updated: 2026-07-30